Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378:169–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26:1816–21.

Article  PubMed  PubMed Central  Google Scholar 

Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375:296–301.

Article  CAS  PubMed  Google Scholar 

Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13:25–36.

Article  CAS  PubMed  Google Scholar 

Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol. 2018;31:233–43.

Article  CAS  PubMed  Google Scholar 

Sorensen PS, Sellebjerg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286419836913.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96–120.

Article  PubMed  Google Scholar 

McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325:765–79.

Article  CAS  PubMed  Google Scholar 

Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High-efficacy therapies for treatment-naïve individuals with relapsing-remitting multiple sclerosis. CNS Drugs. 2022;36:1285–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

European Medicines Agency. Mavenclad product information. 2022 [cited 2022 Oct 21]. https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_en.pdf.

Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34:28–35.

Article  CAS  PubMed  Google Scholar 

Wiendl H, Schmierer K, Hodgkinson S, Derfuss T, Chan A, Sellebjerg F, et al. Specific patterns of immune cell dynamics may explain the early onset and prolonged efficacy of cladribine tablets: a MAGNIFY-MS substudy. Neurol Neuroimmunol Neuroinflamm. 2023;10: e200048.

Article  PubMed  Google Scholar 

Wiendl H, De Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, et al. Blood biomarker dynamics in highly active relapsing multiple sclerosis patients treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Poster P008. Mult Scler. 2023;29:18–242.

Google Scholar 

De Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, et al. Early reduction of MRI activity during 6 months of treatment with cladribine tablets for highly active relapsing multiple sclerosis: MAGNIFY-MS. Neurol Neuroimmunol Neuroinflamm. 2022;9: e1187.

Article  PubMed  PubMed Central  Google Scholar 

De Stefano N, Achiron A, Chan A, Derfuss T, Hodgkinson S, Leocani L, et al. Early onset of action and sustained efficacy of MRI outcomes during cladribine tablets treatment in highly active relapsing multiple sclerosis: results of the 2-year MAGNIFY-MS study. ECTRIMS 2022–P717. Mult Scler. 2022;28:130–691.

Google Scholar 

Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168–74.

Article  PubMed  Google Scholar 

Stuve O, Soelberg Soerensen P, Leist T, Giovannoni G, Hyvert Y, Damian D, et al. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Ther Adv Neurol Disord. 2019;12:1756286419854986.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Signori A, Saccà F, Lanzillo R, Maniscalco GT, Signoriello E, Repice AM, et al. Cladribine vs other drugs in MS: merging randomized trial with real-life data. Neurol Neuroimmunol Neuroinflamm. 2020;7: e878.

Article  PubMed  PubMed Central  Google Scholar 

Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, et al. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry. Mult Scler. 2023;29:221–35.

Article  PubMed  Google Scholar 

Alshawaf F, Ahmed S, Al-Hashel J, Alroughani R. Ocrelizumab and cladribine had similar EDSS stability and safety profile in patients with highly active multiple sclerosis (P8–3.011). Neurology. 2023;100:3255.

Article  Google Scholar 

Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, et al. Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge. Neurology. 2019;92:180–92.

Article  PubMed  PubMed Central  Google Scholar 

Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20:653–70.

Article  PubMed  Google Scholar 

Calabresi PA, Kappos L, Giovannoni G, Plavina T, Koulinska I, Edwards MR, et al. Measuring treatment response to advance precision medicine for multiple sclerosis. Ann Clin Transl Neurol. 2021;8:2166–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eshaghi A, Young AL, Wijeratne PA, Prados F, Arnold DL, Narayanan S, et al. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nat Commun. 2021;12:2078.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wattjes MP, Steenwijk MD, Stangel M. MRI in the diagnosis and monitoring of multiple sclerosis: an update. Clin Neuroradiol. 2015;25(Suppl 2):157–65.

Article  PubMed  Google Scholar 

Oreja-Guevara C, ParadigMS Group. Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice. Eur J Neurol. 2015;22(Suppl 2):22–7.

Article  PubMed  Google Scholar 

Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015;138:1863–74.

Article  PubMed  Google Scholar 

Tur C, Moccia M, Barkhof F, Chataway J, Sastre-Garriga J, Thompson AJ, et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol. 2018;14:75–93.

Article  PubMed  Google Scholar 

Giovannoni G, Mathews J. Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician’s review. Neurol Ther. 2022;11:571–95.

Article  PubMed  PubMed Central  Google Scholar 

Nabizadeh F, Mohamadi M, Rahmani S, Rajabi R, Afrashteh F, Najdaghi S, et al. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2023;44:3045–57.

Article  PubMed  Google Scholar 

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–26.

Article  CAS  PubMed  Google Scholar 

Leist TP, Comi G, Cree BAC, Coyle PK, Freedman MS, Hartung H-P, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13:257–67.

Article  CAS  PubMed  Google Scholar 

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24:1594–604.

Article  CAS  PubMed  Google Scholar 

Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10:329–37.

Article  CAS  PubMed  Google Scholar 

Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol. 2013;260:1136–46.

Article  CAS  PubMed  Google Scholar 

Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, et al. Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study. Mult Scler. 2019;25:819–27.

Article  CAS  PubMed  Google Scholar 

Vermersch P, Galazka A, Dangond F, Damian D, Wong SL, Jack D, et al. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment. Curr Med Res Opin. 2021;37:459–64.

Article  CAS  PubMed